KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Project: Research › OTHER

Project Details

StatusFinished
Effective start/end date6/02/15 → 6/12/18